Trial · NCT03583372
Adverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 48
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry mouth | Gastrointestinal disorders | Overall Vibegron 75 mg | 5 | 273 | |
| other | Dry mouth | Gastrointestinal disorders | Overall Tolterodine ER 4 mg | 12 | 232 | |
| other | Nasopharyngitis | Infections and infestations | Overall Vibegron 75 mg | 13 | 273 | |
| other | Nasopharyngitis | Infections and infestations | Overall Tolterodine ER 4 mg | 12 | 232 | |
| other | Urinary tract infection | Infections and infestations | Overall Vibegron 75 mg | 18 | 273 | |
| other | Urinary tract infection | Infections and infestations | Overall Tolterodine ER 4 mg | 17 | 232 | |
| other | Headache | Nervous system disorders | Overall Vibegron 75 mg | 15 | 273 | |
| other | Headache | Nervous system disorders | Overall Tolterodine ER 4 mg | 9 | 232 | |
| other | Hypertension | Vascular disorders | Overall Vibegron 75 mg | 24 | 273 | |
| other | Hypertension | Vascular disorders | Overall Tolterodine ER 4 mg | 20 | 232 | |
| serious | Colitis | Gastrointestinal disorders | Overall Vibegron 75 mg | 1 | 273 | |
| serious | Colitis | Gastrointestinal disorders | Overall Tolterodine ER 4 mg | 0 | 232 | |
| serious | Colitis microscopic | Gastrointestinal disorders | Overall Vibegron 75 mg | 1 | 273 | |
| serious | Colitis microscopic | Gastrointestinal disorders | Overall Tolterodine ER 4 mg | 0 | 232 | |
| serious | Gastric ulcer haemorrhage | Gastrointestinal disorders | Overall Vibegron 75 mg | 0 | 273 | |
| serious | Gastric ulcer haemorrhage | Gastrointestinal disorders | Overall Tolterodine ER 4 mg | 1 | 232 | |
| serious | Appendicitis | Infections and infestations | Overall Vibegron 75 mg | 1 | 273 | |
| serious | Appendicitis | Infections and infestations | Overall Tolterodine ER 4 mg | 1 | 232 | |
| serious | Urosepsis | Infections and infestations | Overall Vibegron 75 mg | 1 | 273 | |
| serious | Urosepsis | Infections and infestations | Overall Tolterodine ER 4 mg | 0 | 232 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03583372/events